Table 1.
Demographic and baseline characteristics of patients included
| Kono-S group n = 30 |
Control group n = 30 |
p value | |
|---|---|---|---|
| Gender f/m (% female) | 14/16 (46.7% f) | 13/17 (43.3% f) | n.s. |
| Age (years [median; IQR]) | 32 [27–46.5] | 33 [27.3–43.3] | n.s. |
| Primary resection/recurrence | 24 (80%) / 6 (20%) | 28 (93.3%)/2 (6.7%) | n.s. |
| BMI [median; IQR] | 23 [19.7–27.7] | 22.6 [19.7–25] | n.s. |
| Duration of disease (years [median; IQR]) | 9.5 [3–15.5] | 8 [3–14.8] | n.s. |
| Perioperative medication | |||
| Prednisone; dose [median; range] | 11 (36.7%); | 11 (36.7%) | n.s. |
| 10 mg [2.5–20] | 20 mg [11–43] | ||
| Budesonide | 8 (26.7%) | 10 (33.3%) | n.s. |
| Thiopurines | 6 (20%) | 3 (10%) | n.s. |
| Methotrexate | 2 (6.7%) | 0 | n.s. |
| Biologics | 19 (63.3%) | 8 (26.7%) | 0.008 |
| Preoperative albumin level (g/l) [median IQR] | 36 [30–38.5] | 36.5 [31.8–40] | n.s. |
| Current smoker | 8 (26.7%) | 7 (23.3%) | n.s. |
| Preoperative interval between biologic medication and surgery | Days (median) | Days (median) | |
| All patients (n = 19 vs. n = 8) | 36.5 | n.a. | |
| Infliximab (n = 6 vs. n = 2) | 41.5 | 1 × 42; 1× unknown | n.a. |
| Vedolizumab (n = 4 vs. n = 2) | 50 | 1 × 44; 1× unknown | n.a. |
| Adalimumab (n = 3 vs. n = 3) | 13 | 22; 1× unknown | n.a. |
| Certolizumab (n = 2 vs. n = 1) | 21 | 1 × 42 | n.a. |
| Ustekinumab (n = 1 vs. n = 0) | 42 | ||